Viralgen Vector Core

Viralgen Vector Core Contract Manufacturing & Development (CDMO) Profile

At Viralgen we specialize in the production of rAAV viral vectors, and have built an optimized facility that maximizes throughput and efficiency of our proprietary Pro10â„¢ suspension manufacturing platform, enabling industry-leading scalability, reproducibility, and speed to market.

Through our superior technology platform, we deliver industry- leading titers and cGMP-certified quality for all AAV serotypes to our client partners, optimize the cost-of-goods and accelerate clinical development and commercialization of life-saving genetic medicines.

We combine decades of technology and drug development experience in multiple platforms to support best-in-class service offerings to the gene therapy market.

CDMO Services:
Cell & Gene Therapy Sterile Vials Analytical Development; Formulation Development; ICH Stability Testing; Process Development Viral Vector Vaccines

Year Founded: 2017

Head Office: San Sebastián, Spain

Number of Facilities: 1-2

Facility locations: Europe

Website: Visit the Viralgen Vector Core website

Linkedin: Connect on Linkedin

Current Capacity: – 50L-250L scale to supply Toxicology/biodistribution studies.​

– 7 independent state-of-the-art cGMP production suites, in two facilities providing the capability to continuously manufacture 7 different products simultaneously.​

Viralgen uses 250L, 500L single-use stirred-tank bioreactors for culture of suspension cells in clinical manufacturing.​

​Up to 2000L bioreactors in the commercial facility.​

​In-house QC lab for critical release assays. ​

Internal Process, Analytical Development and MSAT labs​

​